Charles E Sheedy bought $200k of AURX
owner at Nuo Therapeutics, Inc.. 133,333 shares at an average of $1.50, traded Jul 30, 2025, filed Aug 1, 2025.
Score components
- +12Role10% owner
- +12Trade size$200k at market
- 0Relative to holdingsHoldings up 1.2%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -6.3%, 3m +14.9%, 6m -0.5%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001437749-25-024427, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jul 30, 2025 | POpen-market purchase Common Stock | +133,333 | $1.50 | $200k | 11,570,833 | Aug 1, 2025 |
Related signals
Other insiders at Nuo Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 28Weak | AURXbuy Nuo Therapeutics, Inc. | David Emerson Jorden CEO/CFO | $9,539 8,773 shares | +0% | |
| 39Weak | AURXsell Nuo Therapeutics, Inc. | David Emerson Jorden CEO/CFO | $300k 200,000 shares | -9% | |
| 23Weak | AURXbuy Nuo Therapeutics, Inc. | Charles E Sheedy owner | $75k 150,000 shares | +1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.